Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Chem Neuroanat ; 110: 101855, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33031915

RESUMEN

OBJECTIVE(S): Although the available therapeutic agents alleviate the symptoms in patients with temporal lobe epilepsy (TLE), these antiepileptic drugs do not provide adequate control of seizures in 30-40 % of patients. This study was conducted to evaluate anti-epileptic effects of simultaneous inhibition of dipeptidyl peptidase-4 and P2 × 7 purinoceptors in Kainate treated rats. MATERIALS AND METHODS: Brilliant Blue G)BBG(, linagliptin)lin(and lin + BBG were administrated 30 min prior to induction of the intrahippocampal kainate model of epilepsy in male Wistar rats. In the case of valproic acid group, the animals intraperitoneally received valproic acid for 7 consecutive days prior to induction of the model. We carried out histological evaluations, monitoring of behavior, recording of intracranial electroencepholography (IEEG), and determination of astrogliosis and DNA fragmentation using ELISA methods. RESULTS: Our results showed that BBG and lin combination therapy had better effects on decrease in astrogliosis, DNA fragmentation and cognitive disturbances than ones whereas its effects on neuronal survival and seizure severity was similar to only BBG or lin. Likewise, the effects of lin + BBG on decrease in DNA fragmentation and cognitive disturbances were better than valproic acid group. CONCLUSION: Our findings suggest that simultaneous inhibition of dipeptidyl peptidase-4 and P2 × 7 purinoceptors might more efficiently provide protection against progression of the kainate-induced TLE in rats.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Inhibidores de la Dipeptidil-Peptidasa IV/uso terapéutico , Epilepsia/tratamiento farmacológico , Antagonistas del Receptor Purinérgico P2Y/uso terapéutico , Convulsiones/tratamiento farmacológico , Animales , Anticonvulsivantes/administración & dosificación , Fragmentación del ADN/efectos de los fármacos , Inhibidores de la Dipeptidil-Peptidasa IV/administración & dosificación , Modelos Animales de Enfermedad , Quimioterapia Combinada , Electroencefalografía , Epilepsia/inducido químicamente , Epilepsia/fisiopatología , Gliosis/tratamiento farmacológico , Gliosis/fisiopatología , Hipocampo/efectos de los fármacos , Hipocampo/fisiopatología , Ácido Kaínico , Linagliptina/administración & dosificación , Linagliptina/uso terapéutico , Masculino , Antagonistas del Receptor Purinérgico P2Y/administración & dosificación , Ratas , Ratas Wistar , Colorantes de Rosanilina/administración & dosificación , Colorantes de Rosanilina/uso terapéutico , Convulsiones/inducido químicamente , Convulsiones/fisiopatología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...